Fstar Therapeutics Stock Operating Margin
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess FStar Therapeutics' long-term financial health and intrinsic value.
FStar |
FStar Therapeutics Company Operating Margin Analysis
FStar Therapeutics' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current FStar Therapeutics Operating Margin | (1.62) % |
Most of FStar Therapeutics' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, FStar Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
CompetitionBased on the recorded statements, FStar Therapeutics has an Operating Margin of -1.6223%. This is 95.38% lower than that of the Healthcare sector and 98.55% lower than that of the Biotechnology industry. The operating margin for all United States stocks is 70.56% lower than that of the firm.
FStar Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses FStar Therapeutics' direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of FStar Therapeutics could also be used in its relative valuation, which is a method of valuing FStar Therapeutics by comparing valuation metrics of similar companies.FStar Therapeutics is currently under evaluation in operating margin category among its peers.
FStar Fundamentals
| Return On Equity | -0.61 | |||
| Return On Asset | -0.22 | |||
| Profit Margin | (2.11) % | |||
| Operating Margin | (1.62) % | |||
| Current Valuation | 98.23 M | |||
| Shares Outstanding | 21.98 M | |||
| Shares Owned By Insiders | 3.71 % | |||
| Shares Owned By Institutions | 44.90 % | |||
| Number Of Shares Shorted | 1.27 M | |||
| Price To Book | 2.13 X | |||
| Price To Sales | 5.47 X | |||
| Revenue | 21.17 M | |||
| Gross Profit | 21.17 M | |||
| EBITDA | (30.17 M) | |||
| Net Income | (31.28 M) | |||
| Cash And Equivalents | 35.57 M | |||
| Cash Per Share | 1.62 X | |||
| Total Debt | 9.61 M | |||
| Debt To Equity | 0.22 % | |||
| Current Ratio | 3.38 X | |||
| Book Value Per Share | 2.59 X | |||
| Cash Flow From Operations | (27.27 M) | |||
| Short Ratio | 1.88 X | |||
| Earnings Per Share | (1.83) X | |||
| Target Price | 7.0 | |||
| Number Of Employees | 84 | |||
| Beta | -0.35 | |||
| Market Capitalization | 156.51 M | |||
| Total Asset | 123.02 M | |||
| Z Score | 9.6 | |||
| Net Asset | 123.02 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Other Consideration for investing in FStar Stock
If you are still planning to invest in FStar Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the FStar Therapeutics' history and understand the potential risks before investing.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |